Like this article?
Get your free daily medical news from Physician's First Watch.
FDA Probes Agents Affecting Clopidogrel Response
The FDA is investigating whether the antiplatelet drug clopidogrel is less effective in people with some genetic factors and when taken with other drugs, including proton pump inhibitors (PPIs).
Studies indicate that certain polymorphisms may cause patients to metabolize clopidogrel differently.
In addition, research has shown that PPIs inhibit the enzyme that converts clopidogrel to its active form, potentially rendering it less effective. (Clopidogrel and PPIs are commonly used in tandem because clopidogrel can irritate the stomach, while PPIs decrease stomach acid.)
Until the manufacturers have finished further studies, the FDA recommends that healthcare providers:
- continue to prescribe clopidogrel, because of its demonstrated benefits;
- reevaluate the need for a PPI if a patient is taking clopidogrel.
LINK(S):
FDA early communication (Free)
Physician's First Watch coverage of previous studies on genotype and clopidogrel response (Free)
Published in Physician's First Watch January 27, 2009
Your Remark:
To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.